Study of obinutuzumab for chronic inflammatory demyelinating polyradiculoneuropathy
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests whether a drug called obinutuzumab can help people with chronic inflammatory demyelinating polyradiculoneuropathy (a condition where the immune system attacks the nerves, causing weakness and numbness). The drug aims to reduce the immune attack and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have a confirmed diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) based on specific medical criteria.
- Your symptoms must be active and affect your daily life (score of 2 or more on a disability scale).
- You cannot have certain other nerve conditions or diseases that could explain your symptoms.
- You must not have had certain treatments (like rituximab, methotrexate, or high-dose steroids) within the last 6 months.
- You must be willing to use effective birth control during the study and for 12 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well current treatments work for people with CIDP (a nerve condition causing weakness). It tracks symptoms and daily function over time to help doctors understand which treatments may work best.
This trial tests nipocalimab (an antibody medicine) to improve symptoms and control activity in chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease that causes weakness and numbness. It may help reduce disease activity and disability, while checking safety.
This trial tests whether a new medicine called imeroprubart can help people with CIDP, a nerve condition causing weakness and numbness. It may provide an alternative to current treatments like steroids or immunoglobulin therapy.
This trial tests a new drug called DNTH103 for adults with CIDP, a condition that affects nerves and causes weakness. It aims to see if the drug can help people who are currently on treatment, have tried treatment before, or are new to treatment.
This study uses ultrasound to look at nerves in people with CIDP to help guide treatment. It aims to see if ultrasound can help doctors choose the best therapy for each person.
This trial tests whether a blood-filtering treatment called immunoadsorption can help people with CIDP. It is for adults who are already receiving or starting IVIg or MP therapy.
Hear when a new Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.